← back to search

Emanuela Palmerini

Istituto Ortopedico Rizzoli · IT
Area of research
Pulmonary and Respiratory Medicine · Rheumatology
Research interest
Research interests include Sarcoma Diagnosis and Treatment, Bone Tumor Diagnosis and Treatments, Musculoskeletal synovial abnormalities and treatments, and Vascular Tumors and Angiosarcomas.
h-index
53
citations
12,133
works
331
NIH funding
primary concept
Medicine
email

Recent publications

Reply to: Mifamurtide in Nonmetastatic High-Grade Osteosarcoma.
2026cited by 0position: contributordoi
Consensus recommendations in the management of jaw (gnathic) osteosarcoma.
2026cited by 0position: contributordoi
Current Treatment Strategies for Diffuse Tenosynovial Giant Cell Tumor: A Review of the Literature.
2026cited by 0position: contributordoi
Integrated Immune and Molecular Profiling Identifies Prognostic Subgroups and Therapeutic Targets in Chondrosarcoma.
2026cited by 0position: contributordoi
Mapping Genomic Heterogeneity in Pediatric and Adolescent-Young Adult Sarcomas: Insights from the Italian SAR-GEN2016 and SAR-GEN_ITA Prospective Multicenter Trials.
2026cited by 0position: contributordoi
Initial report from the SAR-TRACK (SELNET) registry: a multicentric international retrospective analysis on the quality of the management of limb and trunk wall soft-tissue sarcomas (2012–2022) in Ibero-American countries
The Lancet Regional Health - Americas 2026cited by 0position: contributordoi
Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm, phase 2 trial.
2025cited by 14position: contributordoi
Medical Management of Tenosynovial Giant Cell Tumor
Current Oncology Reports 2025cited by 6position: firstdoi
Clear Cell Sarcoma of Soft Tissues: Radiological Analysis of 14 Patients—MRI Findings Related to Metastatic Disease
Diagnostics 2025cited by 5position: middledoi
Prognostic Factors in Newly Diagnosed High‐Grade Osteosarcoma—A Systematic Review
Cancer Medicine 2025cited by 5position: middledoi
Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials
Journal of Clinical Oncology 2025cited by 5position: firstdoi
Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
Clinical Cancer Research 2025cited by 4position: firstdoi
Extended molecular profiling in mesenchymal tumors: a consensus paper from the Italian Sarcoma Group.
2025cited by 3position: contributordoi
Prognostic Factors in Newly Diagnosed High-Grade Osteosarcoma-A Systematic Review.
2025cited by 3position: contributordoi
Clear Cell Sarcoma of Soft Tissues: Radiological Analysis of 14 Patients-MRI Findings Related to Metastatic Disease.
2025cited by 3position: contributordoi
Extended molecular profiling in mesenchymal tumors: a consensus paper from the Italian Sarcoma Group
Critical Reviews in Oncology/Hematology 2025cited by 3position: middledoi
Prognostic factors in patients with relapsed high-grade osteosarcoma: a systematic review
British Journal of Cancer 2025cited by 2position: middledoi
Radiomics in Soft Tissue Sarcoma: Toward Precision Imaging in Oncology
Cancers 2025cited by 2position: middledoi
The landscape of Functional Outcome Measures Used in Patients with Bone Sarcoma of the Lower Extremity or Pelvis: A Systematic Review.
2025cited by 2position: contributordoi
Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials.
2025cited by 2position: contributordoi
Recurrent and Refractory Ewing Sarcoma Phase I/II Trials: Current Perspective From the Euro-Ewing Consortium
JCO Precision Oncology 2025cited by 1position: middledoi
Histopathological Response After Neoadjuvant Chemotherapy for High-Risk Soft-Tissue Sarcomas: A Secondary Analysis of a Randomized Clinical Trial.
2025cited by 1position: contributordoi
Radiomics in Soft Tissue Sarcoma: Toward Precision Imaging in Oncology.
2025cited by 1position: contributordoi
Imaging Analysis for Metastatic Risk Assessment in Adamantinoma: The Aid of Radiology in the Absence of a Histological Grading-An MRI-Based Risk Model Proposal.
2025cited by 1position: contributordoi
Prognostic factors in patients with relapsed high-grade osteosarcoma: a systematic review.
2025cited by 1position: contributordoi
Recurrent and Refractory Ewing Sarcoma Phase I/II Trials: Current Perspective From the Euro-Ewing Consortium.
2025cited by 1position: contributordoi
Tumor Immune Microenvironment-Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial.
2025cited by 1position: contributordoi
Intensified Induction Therapy for Newly Diagnosed, Localized Skeletal Ewing Sarcoma (ISG/AIEOP EW-1): A Randomized, Open-Label, Phase 3, Non-Inferiority Trial.
2025cited by 1position: contributordoi
VEGF Signaling Pathway Germline Polymorphisms as Prognostic Pharmacogenetic Biomarkers in Localized High-Grade Osteosarcoma Patients from the GEIS-33 Protocol.
2025cited by 0position: contributordoi
Genomic Profiling of Highly Aggressive Musculoskeletal Sarcomas Identifies Potential Therapeutic Targets: A Single-Center Experience.
2025cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 78 papers (2019–2026)Javier Martín‐Broto · University of Miami33 papers (2019–2026)Angelo Paolo Dei Tos · University of Padua32 papers (2018–2025)Silvia Stacchiotti · Dana-Farber Cancer Institute26 papers (2013–2025)Marco Gambarotti · Hospital Universitario Fundación Jiménez Díaz22 papers (2019–2026)Jean‐Yves Blay · International Network for Economic, Social and Cultural Rights22 papers (2013–2026) · 21 papers (2021–2026)Davide María Donati · Leiden University Medical Center19 papers (2019–2025)Katia Scotlandi · Istituti di Ricovero e Cura a Carattere Scientifico18 papers (2021–2025) · 17 papers (2021–2026)Paolo G. Casali · Fondazione IRCCS Istituto Nazionale dei Tumori17 papers (2013–2025)Alessandro Gronchi · Northwestern University15 papers (2021–2024) · 15 papers (2021–2023) · 15 papers (2021–2026)Domenico Franco Merlo · University of Pavia15 papers (2020–2023)Paola Collini · Fondazione IRCCS Istituto Nazionale dei Tumori14 papers (2021–2023)Giovanni Grignani · Hospital Universitario Fundación Jiménez Díaz14 papers (2017–2024)Daniel Lopez-Lopez · Instituto de Investigación de Enfermedades Raras13 papers (2021–2023)Salvatore L. Renne · Hospital Universitario Fundación Jiménez Díaz13 papers (2021–2023) · 13 papers (2021–2023)